A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator.

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Four more people with nonactive secondary progressive multiple sclerosis (SPMS ... Treatment with the investigational BTK inhibitor tolebrutinib significantly delayed the onset of confirmed ...

Reduction in spleen volume of ≥35% from baseline at week 24 was met in 65.9 and 35.2% of patients randomly assigned to pelabresib-ruxolitinib and placebo-ruxolitinib, respectively. HealthDay ...

Results of a post hoc analysis of 3 phase 3 trials of tolebrutinib suggest that PRLs are associated with an increased risk for disability accumulation in MS. Results of a post hoc analysis of 3 phase ...

However, only about a year ago, she was rebounding from serious complications of multiple sclerosis (MS). Multiple sclerosis is a chronic disease of the central nervous system in which a person’s body ...

is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation ...